Brief: Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement
02/12/2024 12:04
Dec 2 (Reuters) - Olema Pharmaceuticals OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL COLLABORATION
AND
SUPPLY AGREEMENT WITH NOVARTIS IN FRONTLINE METASTATIC BREAST
CANCER AS WELL AS $250 MILLION EQUITY PRIVATE PLACEMENT
* OLEMA PHARMACEUTICALS INC - WELL CAPITALIZED TO FUND
OPERATIONS
BEYOND KEY MILESTONES
Source text: ID:nGNX5SNQcx
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs